An evaluation of the duration of efficacy of emamectin benzoate in the control of Caligus curtus Müller infestations in Atlantic cod, Gadus morhua L

The duration of efficacy of emamectin benzoate in the control of Caligus curtus infestations in Atlantic cod, Gadus morhua L., was studied following an administration of 50 μg kg^?1 for seven consecutive days. No lice were found on medicated fish when challenged 1 week (challenge 1) or 5 weeks (challenge 2) following termination of medication, whereas the mean abundance of lice among the unmedicated fish was 17.9 and 19.3 lice per fish in challenge 1 and 2, respectively. Muscle concentrations of 19.5 ± 8.2 ng g^?1 and 3.4 ± 0.9 ng g^?1, respectively, and skin concentrations of 23.1 ± 10.8 and 4.2 ± 1.0 ng g^?1, respectively, were found 27 and 55 days following the termination of medication. Tissue concentrations and the duration of efficacy indicate a dosing regime for emamectin in cod, similar to the regime used for Atlantic salmon, Salmo salar L.     

Oxygen binding properties of three different hemoglobin genotypes in turbot (Scophthalmus maximus Rafinesque): Effect of temperature and pH

The aim of this study was to investigate the oxygen binding properties of the turbot (Scophthalmus maximus) hemoglobin polymorphism with special references to pH and temperature. Hemolysate samples from the three hemoglobin genotypes Hb- I(1/1), Hb-I(1/2) and Hb-I(2/2), were tested at 10, 16 and 19 °C and at pH values 7.2, 7.5 and 7.8 at 100 mm NaCl respectively. Hb-I(2/2) had the highest oxygen affinity at all three temperatures followed by Hb- I(1/2) and Hb-I(1/1). There was a significant decrease in oxygen affinity with increasing temperature and increasing pH in the range 10 to 19 °C for all three genotypes. The genotype Hb-I(1/1) had the highest Bohr effect followed by genotype Hb-I(2/2) and Hb-I(1/2). The effect was highest at 10 °C and decreased with temperature. Temperature sensitivity of the O2 binding for turbot hemoglobin was low and increased in general with increasing pH. It is hypothesised that the low sensitivity hemoglobins may be an adaptation to variable temperature conditions in the distribution area of the species.     

A single-dose pharmacokinetic study of oxolinic acid and vetoquinol,an oxolinic acid ester,in cod,Gadus morhua L., held in sea water at 8 degrees C and in vitro antibacterial activity of oxolinic acid against Vibrio anguillarum strains isolated from diseased cod

The pharmacokinetic properties of the antibacterial agent oxolinic acid and vetoquinol, the carbitol ester of oxolinic acid, were studied after intravenous (i.v.) and oral (p.o.) administration to 100-150 g cod, Gadus morhua L., held in sea water at 8 degrees C. Following i.v. injection, the plasma drug concentration-time profile showed two distinct phases. The distribution half-life (t1/2alpha) was estimated at 1.3 h, the elimination half-life (t1/2beta) as 84 h and the total body clearance (Cl(T)) as 0.047 L kg(-1) h(-1). The volume of distribution at steady state, Vd(ss) was calculated to be 5.5 L kg(-1), indicating good tissue penetration of oxolinic acid in cod. Following p.o. administration of oxolinic acid or vetoquinol, the peak plasma concentrations (C(max)) of oxolinic acid and the time to peak plasma concentrations (T(max) were estimated to be 1.2 and 2.5 microg mL(-1) and 24 and 12 h, respectively. The bioavailabilities of oxolinic acid following p.o. administration of oxolinic acid and vetoquinol were calculated to be 55 and 72%, respectively. The in vitro minimum inhibitory concentration (MIC) values of oxolinic acid against three strains of Vibrio anguillarum isolated from diseased cod were 0.016 microg mL(-1) (HI-610), 0.250 microg mL(-1) (HI-618) and 0.250 microg mL(-1) (HI-A21). Based on a MIC value of 0.016 microg mmL(-1) a single p.o. administration of 25 mg kg(-1) of oxolinic acid maintains plasma levels in excess of 0.064 microg mL(-1), corresponding to four times the MIC-value, for approximately 12 days. The analogous value for a single p.o. dose of 25 mg kg(-1) of oxolinic acid administered as vetoquinol was 13 days.     

Pharmacokinetic and efficacy studies on bath-administering potentiated sulphonamides in Atlantic halibut, Hippoglossus hippoglossus L.

The uptake, metabolism, tissue distribution and excretion of four sulphonamides and trimethoprim following bath treatment of Atlantic halibut, Hippoglossus hippoglossus L., were studied. Bath treatment using a concentration of 200 μg ml^–1 for 72 h resulted in peak sulphadimidine concentrations in muscle and abdominal organ homogenates of 32·6 and 68·2 μg g^–1, respectively. The corresponding values were 24·4 and 73·4 μg g^–1 for sulphaguanidine, 6·1 and 45·1 μg g^–1 for sulphamethoxazole, 2·1 and 15·1 μg g^–1 for sulphadimethoxine, and 99 and 169 μg g^–1 for trimethoprim. After a 72-h treatment, approximately 90% of the sulphadimethoxine and sulphamethoxazole present in tissues was found as the N⁴-acetylated metabolite, whereas for sulphadimidine and sulphaguanidine, the N⁴-acetylations were from 9 to 23%. Based on these preliminary absorption studies, sulphadimidine was chosen as the companion sulphonamide to trimethoprim. Using a combination of 500 μg ml^–1 sulphadimidine and 100 μg ml^–1 trimethoprim in the bath for 72 h, peak muscle and liver concentrations of 262 and 312 μg g^–1, respectively, for sulphadimidine and 32·8 and 83·6 μg g^–1, respectively, for trimethoprim were achieved. Elimination half-lives (t_1/2β) for sulphadimidine were calculated to be 35 and 48 h for muscle and liver, respectively. The corresponding values for trimethoprim were 98 and 116 h. Using the 95% confidence limit for single observations (95% prediction limit) and a maximum residue limit (MRL) value of 0·05 μg g^–1 for trimethoprim and 0·1 μg g^–1 for sulphadimidine, the elimination times (E_t95) for muscle and liver were calculated to be 18 and 26 days, respectively, for sulphadimidine and 40 and 55 days, respectively, for trimethoprim. Minimum inhibitory concentrations (MIC) values against selected strains of Vibrio sp. were equal to or above 128 μg ml^–1 for sulphadimidine, between 0·25 and 4·00 μg ml^–1 for trimethoprim and between 0·4 and 8·8 μg ml^–1 for various ratios of the sulphadimidine:trimethoprim combination. In the tested ratios, the combined antimicrobial action of trimethoprim and sulphadimidine were synergistic, as revealed by their fractional inhibitory concentration (FIC) indices. In general, the 1:5 trimethoprim sulphadimidine ratio showed the highest degree of synergism. Using a combination of 500 μg ml^–1 sulphadimidine and 100 μg ml^–1 trimethoprim in the bath for 72 h, concentrations greater than a MIC value of 0·8 μg ml^–1 were maintained for 22 days in muscle and 29 days in liver. In a laboratory challenge experiment using Vibrio anguillarum strain HI 11347, a significantly lower mortality was observed in the drug-treated group (40%) compared to the untreated control group (93%).     

Absorption, tissue distribution and excretion of flumequine and oxolinic acid in corkwing wrasse (Symphodus melops) following a single intraperitoneal injection or bath treatment

The pharmacokinetic properties of the antibacterial agents oxolinic acid and flumequine were studied in corkwing wrasse (Symphodus melops) after either intraperitoneal injection or bath treatment. Following intraperitoneal administration the peak plasma concentrations (Cmax) and the time to peak plasma concentrations (Tmax) were estimated to be 2.0 microg/mL and 12 h, respectively, for oxolinic acid and 2.6 microg/mL and 12 h, respectively, for flumequine. In muscle, Cmax and Tmax were estimated to 6.7 microg/g and 12 h, respectively, for oxolinic acid with corresponding values of 8.5 microg/g and 13 h, respectively, for flumequine. In liver, Cmax and Tmax were calculated to 7.0 microg/g and 12 h, respectively, for oxolinic and 12.2 microg/g and 11 h, respectively, for flumequine. Elimination half-lives (t1/2 beta) of 26, 24 and 29 h, respectively, for plasma, muscle and liver were calculated for flumequine. For oxolinic acid two distinct elimination phases were found and calculated to be 16 h (t1/2 beta) and 57 h (t1/2 gamma) in plasma, 15 and 59 h, respectively, in muscle and 20 and 72 h, respectively, in liver. Bath treatment using 150 mg/L of flumequine or 200 mg/L of oxolinic acid for 72 h resulted in flumequine concentrations of 1.0 microg/mL in plasma, 5.0 microg/g in muscle and 12.4 microg/g in liver. Corresponding values for oxolinic acid were 1.0 microg/g in plasma, 2.5 microg/g in muscle and 4.9 microg/g in liver.     

Susceptibility of corkwing wrasse Symphodus melops, goldsinny wrasse Ctenolabrus rupestis, and Atlantic salmon Salmo salar smolt, to experimental challenge with Vibrio tapetis and Vibrio splendidus isolated from corkwing wrasse

The virulence of two Vibrio strains, previously isolated from diseased corkwing wrasse Symphodus melops and identified as V. tapetis and V. splendidus, to corkwing and goldsinny wrasse Ctenolabrus rupestris and to Atlantic salmon Salmo salar, was studied under laboratory conditions. Both bacteria were shown to be opportunistically pathogenic to corkwing wrasse, causing significantly higher mortality in the challenged groups than in the controls. Bacterial cultivation of kidney samples and re-isolation of V. tapetis and V. splendidus from most mortalities confirmed the two strains as the probable cause of mortality in the challenged groups. The control group also suffered relatively high mortality, but no specific pathogens that were suspected to be the main cause of death were isolated, other than a mixture of Vibrio spp. and, in the case of one individual, atypical Aeromonas salmonicida. Following injection challenge with both bacterial strains, no mortality was recorded in Atlantic salmon. In bath challenge trials with goldsinny wrasse, only slight mortality was observed in the challenged groups and the unchallenged control group. Bacterial examination showed that atypical Aeromonas salmonicida was the probable cause of death in both bath challenged and control groups of goldsinny wrasse, and no indication of infection by any Vibrio sp. was found.     

Antioxidant and 15-lipoxygenase inhibitory activity of rotenoids, isoflavones and phenolic glycosides from Sarcolobus globosus

From Sarcolobus globosus, two rotenoids (villosinol and 6-oxo-6a,12a-dehydrodeguelin), one isoflavone (genistin) and four phenolic glycosides (vanillic acid 4-O-beta-d-glucoside, glucosyringic acid, tachioside and isotachioside) were identified for the first time from this species. Extracts and compounds from S. globosus were evaluated for their DPPH radical scavenging and 15-lipoxygenase (15-LO) inhibitory activities. All tested rotenoids were found to inhibit 15-LO, while they lacked DPPH radical scavenging effect.     

A single‐dose pharmacokinetic study of emamectin benzoate in cod,Gadus morhua L., held in sea water at 9 °C

The pharmacokinetic profile of the antiparasitic agent emamectin benzoate was studied in plasma after intravenous (i.v.) injection and in plasma, muscle and skin following oral (p.o.) administration to cod, Gadus morhua, held in sea water at 9 °C and weighing 100–200 g. Following i.v. injection, the plasma drug concentration‐time profile showed two distinct phases. The plasma distribution half‐life (t_1/2α) was estimated as 2.5 h, the elimination half‐life (t_1/2β) as 216 h, the total body clearance (Cl_T) as 0.0059 L kg^?1 h^?1 and mean residence time (MRT) as 385 h. The volume of distribution at steady state, V_d(ss), was calculated to be 1.839 L kg^?1. Following p.o. administration the peak plasma concentration (C_max) was 15 ng mL^?1, the time to peak plasma concentration (T_max) was 89 h and t_1/2β was 180 h. The highest concentration in muscle (21 ng g^?1) was measured after 7 days and t_1/2β was calculated to be 247 h. For skin, a peak concentration of 28 ng g^?1 at 3 days was observed and a t_1/2β of 235 h was determined. The bioavailability following p.o. administration was calculated to be 38%.     

Evaluating bioencapsulation of florfenicol in rotifers (Brachionus plicatilis)

The rotifer Brachionus plicatilis is one of the most important live‐feed organisms used in the larval culture of marine fish. Bioencapsulation of florfenicol in rotifers was investigated by delivering it directly to the organisms as particles and the doses ranged from 50 to 1000 mg L^?1. Analysis of the florfenicol concentrations in rotifers was performed using high‐performance liquid chromatography. The uptake increased with the dose and the enrichment time, and the highest concentration achieved in this study, 1.25 ng rotifer^?1, was obtained using a dose of 1000 mg L^?1 and 150 min of enrichment. The optimal time for satisfactory enrichment of rotifers with florfenicol was found to be dose dependent and ranged from 30 to 120 min for doses between 400 and 800 mg L^?1. The parameters affecting the concentrations achieved in rotifers were the size of the florfenicol particles, enrichment time and dose.